SG Americas Securities LLC Raises Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

SG Americas Securities LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 407.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,958 shares of the company’s stock after buying an additional 8,797 shares during the period. SG Americas Securities LLC’s holdings in Twist Bioscience were worth $495,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the second quarter valued at about $43,000. Blue Trust Inc. increased its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter valued at about $61,000. Nisa Investment Advisors LLC increased its holdings in Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after buying an additional 546 shares in the last quarter. Finally, CWM LLC increased its holdings in Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares in the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the transaction, the chief financial officer now owns 73,397 shares of the company’s stock, valued at $3,068,728.57. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now owns 88,837 shares of the company’s stock, valued at $3,547,261.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now directly owns 73,397 shares in the company, valued at approximately $3,068,728.57. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,246 shares of company stock valued at $1,829,356 over the last quarter. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $45.07 on Thursday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The firm’s 50 day moving average price is $43.91 and its 200 day moving average price is $44.20.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. During the same quarter last year, the business posted ($1.01) EPS. The firm’s revenue was up 27.7% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

TWST has been the topic of several research reports. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays lowered their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. The Goldman Sachs Group increased their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.63.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.